Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN65,1165,142,13
Msft-0,17
Nokia3,29053,2965-1,02
IBM0,08
Mercedes-Benz Group AG73,8573,870,39
PFE-0,11
29.03.2024 1:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 28.03.2024 18:59:23
Biotest AG Preferred Stock (BIOG_p.F, Frankfurt)
Závěr k 28.3.2024 Změna (%) Změna (EUR) Objem obchodů (EUR)
26,40 -1,49 -0,40 5 129
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 29.03.2024
Popis společnosti
Obecné informace
Název společnostiBiotest AG
TickerBIO
TickerBIO3
Kmenové akcie:Ordinary Shares
Kmenové akcie:Preference Shares
RICBIOG_p.DE
RICBIOG.DE
ISINDE0005227235
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky31.12.2023
Počet zaměstnanců k 30.06.2023 2 307
Akcie v oběhu k 30.09.2023 39 571 452
MěnaEUR
Kontaktní informace
UliceLandsteinerstr. 5
MěstoDREIEICH
PSČ63303
ZeměGermany
Kontatní osoba 
Funkce kontaktní osoby 
Telefon4 961 038 010
Fax496103801150

Business Summary: Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology and intensive care medicine. Biotest AG develops, manufactures and markets immunoglobulin, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.
Financial Summary: BRIEF: For the nine months ended 30 September 2023, Biotest AG revenues increased 39% to EUR500.3M. Net income totaled EUR88.4M vs. loss of EUR34.2M. Revenues reflect Therapy segment increase of 13% to EUR359.9M, Intercontinental segment increase of 3% to EUR65.8M. Net Income reflects Other Operating Income increase from EUR1.4M to EUR25.2M (income), Other Non-Operating Income (Expense) increase from EUR0K to EUR100K (income).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Biopharmaceuticals
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSIn-Vitro Diagnostic Substance Manufacturing
NAICSBiological Product (except Diagnostic) Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007In-Vitro Diagnostic Substance Mfg
NAICS2007Biological Product (exc Diagnostic) Mfg
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997InVitro Diagnostic Substance Manufacturing
NAICS1997Biological Product (except Diagnostic) Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICDiagnostic Substances
SICBiological Prod's Not Diagnostic
SICCommercial Physical Research



  • Poslední aktualizace: 29.03.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Supervisory BoardBernhard Ehmer6805.05.202201.11.2014
Chairman of the Management Board, Chief Executive OfficerMichael Ramroth6201.01.2004
Deputy Chairman of the Supervisory BoardTomas Gelabert-05.06.202205.05.2022
Chief Financial Officer, Member of the Management BoardAinhoa Zubiaga-15.02.202315.02.2023
Group Finance and Treasury OfficerMartin Moeller-
Chief Operations Officer, Member of the Management BoardPeter Janssen-01.09.202201.09.2022
Chief Scientific Officer, Member of the Management BoardJoerg Schuettrumpf-01.01.2022
Corporate Risk and Compliance OfficerOliver Hein-
Corporate ControllingStephan Fleck-
Head of Marketing and SalesEnrico D'aiuto-